These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21689377)

  • 1. Pharmacophore modeling and density functional theory analysis for a series of nitroimidazole compounds with antitubercular activity.
    Tawari NR; Degani MS
    Chem Biol Drug Des; 2011 Sep; 78(3):408-17. PubMed ID: 21689377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacophore mapping and electronic feature analysis for a series of nitroaromatic compounds with antitubercular activity.
    Tawari NR; Degani MS
    J Comput Chem; 2010 Mar; 31(4):739-51. PubMed ID: 19569203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of 5-substitution on the electrochemical behavior and antitubercular activity of PA-824.
    Bollo S; Núñez-Vergara LJ; Kang S; Zhang L; Boshoff HI; Barry CE; Squella JA; Dowd CS
    Bioorg Med Chem Lett; 2011 Jan; 21(2):812-7. PubMed ID: 21168331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive models for nucleoside bisubstrate analogs as inhibitors of siderophore biosynthesis in Mycobacterium tuberculosis: pharmacophore mapping and chemometric QSAR study.
    Tawari NR; Degani MS
    Mol Divers; 2011 May; 15(2):435-44. PubMed ID: 20306296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine.
    Chaudhari HK; Pahelkar A
    Infect Disord Drug Targets; 2019; 19(2):145-166. PubMed ID: 30324898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, reduction potentials, and antitubercular activity of ring A/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
    Thompson AM; Blaser A; Anderson RF; Shinde SS; Franzblau SG; Ma Z; Denny WA; Palmer BD
    J Med Chem; 2009 Feb; 52(3):637-45. PubMed ID: 19099398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The nitroimidazooxazines (PA-824 and analogs): structure-activity relationship and mechanistic studies.
    Denny WA; Palmer BD
    Future Med Chem; 2010 Aug; 2(8):1295-304. PubMed ID: 21426020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, structure and biological evaluation of novel bicyclic nitroimidazole derivatives.
    Zaprutko L; Zwawiak J; Augustynowicz-Kopeć E; Zwolska Z; Bartoszak-Adamska E; Nowicki W
    Arch Pharm (Weinheim); 2012 Jun; 345(6):463-7. PubMed ID: 22266946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationships of antitubercular nitroimidazoles. 2. Determinants of aerobic activity and quantitative structure-activity relationships.
    Kim P; Kang S; Boshoff HI; Jiricek J; Collins M; Singh R; Manjunatha UH; Niyomrattanakit P; Zhang L; Goodwin M; Dick T; Keller TH; Dowd CS; Barry CE
    J Med Chem; 2009 Mar; 52(5):1329-44. PubMed ID: 19209893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Multiple Linear Regressions and Neural Networks based QSAR models for the design of new antitubercular compounds.
    Ventura C; Latino DA; Martins F
    Eur J Med Chem; 2013; 70():831-45. PubMed ID: 24246731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles.
    Kim P; Zhang L; Manjunatha UH; Singh R; Patel S; Jiricek J; Keller TH; Boshoff HI; Barry CE; Dowd CS
    J Med Chem; 2009 Mar; 52(5):1317-28. PubMed ID: 19209889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Structure-Activity Relationship Study of Naphthoquinone Derivatives as Antitubercular Agents Using Molecular Modeling Techniques.
    Sharma MC
    Interdiscip Sci; 2015 Dec; 7(4):346-56. PubMed ID: 26159131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D-QSAR and cell wall permeability of antitubercular nitroimidazoles against Mycobacterium tuberculosis.
    Lee SH; Choi M; Kim P; Myung PK
    Molecules; 2013 Nov; 18(11):13870-85. PubMed ID: 24217328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacophore assessment through 3-D QSAR: evaluation of the predictive ability on new derivatives by the application on a series of antitubercular agents.
    Friggeri L; Ballante F; Ragno R; Musmuca I; De Vita D; Manetti F; Biava M; Scipione L; Di Santo R; Costi R; Feroci M; Tortorella S
    J Chem Inf Model; 2013 Jun; 53(6):1463-74. PubMed ID: 23617317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Release of nitrite from the antitubercular nitroimidazole drug PA-824 and analogues upon one-electron reduction in protic, non-aqueous solvent.
    Maroz A; Shinde SS; Franzblau SG; Ma Z; Denny WA; Palmer BD; Anderson RF
    Org Biomol Chem; 2010 Jan; 8(2):413-8. PubMed ID: 20066278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Pyrimidines as Antitubercular Agents.
    Inoyama D; Paget SD; Russo R; Kandasamy S; Kumar P; Singleton E; Occi J; Tuckman M; Zimmerman MD; Ho HP; Perryman AL; Dartois V; Connell N; Freundlich JS
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311070
    [No Abstract]   [Full Text] [Related]  

  • 17. Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
    Palmer BD; Thompson AM; Sutherland HS; Blaser A; Kmentova I; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA
    J Med Chem; 2010 Jan; 53(1):282-94. PubMed ID: 19928920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alkylated/aminated nitroimidazoles and nitroimidazole-7-chloroquinoline conjugates: Synthesis and anti-mycobacterial evaluation.
    Shalini ; Viljoen A; Kremer L; Kumar V
    Bioorg Med Chem Lett; 2018 May; 28(8):1309-1312. PubMed ID: 29551480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Progress in the Discovery and Development of 2-Nitroimidazooxazines and 6-Nitroimidazooxazoles to Treat Tuberculosis and Neglected Tropical Diseases.
    Showalter HD
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32927749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and antitubercular activity of monocyclic nitroimidazoles: insights from econazole.
    Lee SH; Kim S; Yun MH; Lee YS; Cho SN; Oh T; Kim P
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1515-8. PubMed ID: 21277200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.